Valuation: EnteroMedics Inc

Market Cap 1.11Cr 99.46L 90.9L 82.98L 1.56Cr 104.24Cr 1.61Cr 11Cr 4.37Cr 56Cr 4.16Cr 4.07Cr 175.59Cr P/E 2026 *
-2.43x
P/E 2027 * -1.98x
Enterprise Value 1.11Cr 99.46L 90.9L 82.98L 1.56Cr 104.24Cr 1.61Cr 11Cr 4.37Cr 56Cr 4.16Cr 4.07Cr 175.59Cr EV / Sales 2026 *
108x
EV / Sales 2027 * 55.4x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 1L 92.38T 84.43T 77.07T 1L 96.82L 1L 10.18L 4L 51.66L 4L 4L 1.63Cr 2L 2L 2L 1L 3L 1.88Cr 3L 19.76L 8L 1Cr 8L 7L 3.17Cr
Net income -44.89L -40.26L -36.79L -33.59L -63.28L -42Cr -65.27L -4.43Cr -1.77Cr -23Cr -1.68Cr -1.65Cr -71Cr -78.46L -70.37L -64.31L -58.71L -1.11Cr -74Cr -1.14Cr -7.75Cr -3.09Cr -39Cr -2.94Cr -2.88Cr -124.24Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-